Dallas Lab Pays $24 Million to Settle Alleged Medicare COVID-19 Testing Fraud Scheme
Dallas-based Magnolia Diagnostics, its owners, and a group of investors have agreed to pay the United States $24 million to resolve allegations that the laboratory billed Medicare for thousands of medically unnecessary respiratory pathogen panel (RPP) tests performed on seniors undergoing COVID-19 testing. Of that total, Magnolia and its owners will pay $19.2 million to resolve allegations under the False Claims Act, while investors will pay a further $4.8 million to resolve civil claims for unjust enrichment, payment by mistake, and claims under the Federal Debt Collection Procedures Act arising from distributions they received from the company.
